Keywords: |
cancer survival; treatment outcome; clinical trial; histopathology; review; cancer recurrence; united states; bone metastasis; cancer staging; flow cytometry; nuclear magnetic resonance imaging; lymph node metastasis; cancer grading; sensitivity and specificity; treatment indication; ki 67 antigen; prostate specific antigen; reproducibility of results; cd34 antigen; protein bcl 2; computer assisted tomography; incidence; angiogenesis; protein p53; prediction; age; prostate cancer; cancer invasion; prostatic neoplasms; tumor suppressor gene; capromab pendetide in 111; diagnostic value; prostatectomy; needle biopsy; protein p27; prostate biopsy; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; predictive value of tests; transforming growth factor beta1; genetic stability; multivariate analysis; hormonal therapy; dna microarray; radioisotope; single photon emission computer tomography; decision making; microvasculature; transrectal ultrasonography; nomogram; perineural invasion; bone scintiscanning; race; clinical examination; chromosome 7q; chromosome 8q; digital rectal examination; continental population groups; microvessel density; ploidy; humans; prognosis; human; male; priority journal; monoclonal antibody ki 67
|